



General Assembly

January Session, 2019

Amendment

LCO No. 7618



Offered by:
SEN. LOONEY, 11th Dist.

To: Senate Bill No. 33

File No. 307

Cal. No. 161

"AN ACT CONCERNING HEALTH INSURANCE COVERAGE OF ORALLY AND INTRAVENOUSLY ADMINISTERED PRESCRIPTION DRUGS."

1 Strike everything after the enacting clause and substitute the
2 following in lieu thereof:

3 "Section 1. Subsection (d) of section 38a-504 of the general statutes is
4 repealed and the following is substituted in lieu thereof (*Effective*
5 *January 1, 2020*):

6 (d) (1) Each policy of the type specified in subsection (a) of this
7 section [that] shall:

8 (A) If such policy provides coverage for intravenously administered
9 and orally administered anticancer medications used to kill or slow the
10 growth of cancerous cells that are prescribed by a prescribing
11 practitioner, as defined in section 20-571, [shall] provide coverage for
12 orally administered anticancer medications on a basis that is no less
13 favorable than intravenously administered anticancer medications;

14 and

15 (B) If such policy provides coverage for intravenously administered
16 and orally administered medications approved by the federal Food
17 and Drug Administration for treatment of disabling or life-threatening
18 chronic diseases that are prescribed by a prescribing practitioner, as
19 defined in section 20-571, provide coverage for such orally
20 administered medications on a basis that is no less favorable than such
21 intravenously administered medications.

22 (2) No insurance company, hospital service corporation, medical
23 service corporation, health care center or fraternal benefit society that
24 delivers, issues for delivery, renews, amends or continues in this state
25 a policy of the type specified in subsection (a) of this section shall
26 reclassify [such anticancer] medications that are subject to subdivision
27 (1) of this subsection or increase the coinsurance, copayment,
28 deductible or other out-of-pocket expense imposed under such policy
29 for such medications to achieve compliance with this subsection.

30 Sec. 2. Subsection (d) of section 38a-542 of the general statutes is
31 repealed and the following is substituted in lieu thereof (*Effective*
32 *January 1, 2020*):

33 (d) (1) Each policy of the type specified in subsection (a) of this
34 section [that] shall:

35 (A) If such policy provides coverage for intravenously administered
36 and orally administered anticancer medications used to kill or slow the
37 growth of cancerous cells that are prescribed by a prescribing
38 practitioner, as defined in section 20-571, [shall] provide coverage for
39 orally administered anticancer medications on a basis that is no less
40 favorable than intravenously administered anticancer medications;
41 and

42 (B) If such policy provides coverage for intravenously administered
43 and orally administered medications approved by the federal Food
44 and Drug Administration for treatment of disabling or life-threatening

45 chronic diseases that are prescribed by a prescribing practitioner, as
46 defined in section 20-571, provide coverage for such orally
47 administered medications on a basis that is no less favorable than such
48 intravenously administered medications.

49 (2) No insurance company, hospital service corporation, medical
50 service corporation, health care center or fraternal benefit society that
51 delivers, issues for delivery, renews, amends or continues in this state
52 a policy of the type specified in subsection (a) of this section shall
53 reclassify [such anticancer] medications that are subject to subdivision
54 (1) of this subsection or increase the coinsurance, copayment,
55 deductible or other out-of-pocket expense imposed under such policy
56 for such medications to achieve compliance with this subsection."

This act shall take effect as follows and shall amend the following sections:

Section 1	<i>January 1, 2020</i>	38a-504(d)
Sec. 2	<i>January 1, 2020</i>	38a-542(d)